TAMPA, Fla., April 8, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that an abstract highlighting Kineta Inc.'s novel KVA12123 antibody and an abstract from Moffitt Cancer Center scientists examining the mechanisms of Company's IFx-Hu2.0 therapy in advanced melanoma have been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL. Details of the accepted abstracts are as follows: Title: Initial result

Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceutic

Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco

Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipelineTargeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapyProposed Transaction expected to close in Q1 2025 TAMPA, FL AND SEATTLE, WA / ACCESSWIRE / December 12, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC:KANT) ("Kineta"), a clinical-stage biotechnology company focused

IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)Entered into a non-binding letter of intent with Kineta regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 expanding its pipeline with a Phase 2 ready, novel VISTA inhibiting antibodyAdvancing IFx-3.0, the first systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell LymphomaEarly discovery programs designing first-in-class t

TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC. As part of the event, Dr. James Bianco, President and Chief Executive Officer of TuHURA participated in the Precision and Immune Oncology panel. To access the webcast replay, sign up to become anM-Vest member.About TuHURA Biosciences, Inc.TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing

Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET TAMPA, FL / ACCESSWIRE / October 22, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, October 30, 2024 at 4:00 PM ET.As part of the event, Dr. Jim Bianco, President and Chief Executive Officer of TuHURA will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and

H.C. Wainwright initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $13.00

Rodman & Renshaw initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $11.00

Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00

425 - TuHURA Biosciences, Inc./NV (0001498382) (Filed by)

425 - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

10-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

S-4 - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

S-8 - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

3 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

SC 13D - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

SC 13D - TuHURA Biosciences, Inc./NV (0001498382) (Subject)